文献速递胸部肿瘤放疗

III期非小细胞肺癌放化疗反应的基因组预测因子分析

Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer.
PubMed 文献 · Adv Radiat Oncol · 2020-11-14

本研究回顾性分析了110例2013至2017年间接受根治性放疗的III期非小细胞肺癌患者,其中104例(95%)接受同步或序贯化疗,并具有肿瘤分子图谱数据。研究发现AKT2突变与局部区域肿瘤控制及总生存下降显著相关,KMT2C和KMT2D有害突变是总生存的不良预后因素,而38个DNA损伤应答与修复通路基因的有害突变与局部区域控制改善相关。

要点

  • AKT2突变与III期NSCLC放化疗后局部区域控制及总生存下降显著相关。
  • KMT2C和KMT2D有害突变是总生存的负性预后因素。
  • DNA损伤应答与修复通路基因有害突变与局部区域控制改善相关。

核心结论

  • AKT2、KMT2C和KMT2D突变是III期NSCLC放化疗后局部区域控制和生存的负性预测因子。
  • DNA损伤应答与修复通路基因的有害突变与放化疗后局部区域疾病控制改善相关。
  • 上述发现需在更大规模、前瞻性收集详细临床信息的队列中验证。

研究设计与样本

  • 回顾性研究,纳入110例2013至2017年间接受根治性放疗且具有下一代DNA测序肿瘤分子图谱的III期NSCLC患者。
  • 104例(95%)患者接受同步或序贯化疗。
  • 采用Cox比例风险模型分析临床结局与下一代测序检测到的基因突变之间的关联。

主要发现

  • AKT2突变与局部区域肿瘤控制下降相关(HR 12.5,P = .003)。
  • AKT2突变与总生存下降相关(HR 13.7,P = .003)。
  • KMT2C有害突变与总生存不良相关(HR 13.4,P < .001)。
  • KMT2D有害突变与总生存不良相关(HR 7.0,P < .001)。
  • 38个DNA损伤应答与修复通路基因panel中的有害突变与局部区域控制改善相关(HR 0.32,P = .049)。

关键数值与推荐

  • AKT2突变:局部区域控制HR 12.5(P = .003),总生存HR 13.7(P = .003)。
  • KMT2C有害突变:总生存HR 13.4(P < .001)。
  • KMT2D有害突变:总生存HR 7.0(P < .001)。
  • DNA损伤应答与修复通路基因panel有害突变:局部区域控制HR 0.32(P = .049)。

临床怎么用

  • 对于III期NSCLC接受根治性放化疗的患者,可考虑检测AKT2、KMT2C、KMT2D及DNA损伤应答与修复通路基因突变以辅助预后分层。
  • AKT2、KMT2C或KMT2D有害突变提示局部区域控制和生存预后较差,可能需要更密切的随访或强化治疗策略。
  • DNA损伤应答与修复通路基因有害突变提示局部区域控制较好,或可支持放化疗决策。

局限性

  • 回顾性研究设计。
  • 样本量有限(110例)。
  • 研究结果需在更大规模、前瞻性收集详细临床信息的队列中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiation with platinum-based chemotherapy is the standard of care for unresectable stage III non-small cell lung cancer (NSCLC). Despite aggressive treatment, progression-free survival and overall survival remain poor. It is unclear whether any tumor genetic mutations are associated with response to chemoradiation therapy. METHODS: We retrospectively reviewed clinical outcomes of patients with stage III NSCLC treated with definitive radiation who had undergone tumor molecular profiling through a next-generation DNA sequencing platform. Cox proportional hazards model was used to investigate associations between clinical outcomes and genetic mutations detected by next-generation sequencing. RESULTS: 110 patients were identified with stage III NSCLC and underwent definitive radiation between 2013 and 2017 and tumor molecular profiling. Concurrent or sequential chemotherapy was given in 104 patients (95%). Unbiased genomic analyses revealed a significant association between AKT2 mutations and decreased local-regional tumor control and overall survival (hazard ratios [HR] 12.5 and 13.7, P = .003 and P = .003, respectively). Analyses restricted to loss-of-function mutations identified KMT2C and KMT2D deleterious mutations as negative prognostic factors for overall survival (HR 13.4 and 7.0, P < .001 and P < .001, respectively). Deleterious mutations in a panel of 38 DNA damage response and repair pathway genes were associated with improved local-regional control (HR 0.32, P = .049). CONCLUSIONS: This study coupled multiplexed targeted sequencing with clinical outcome and identified mutations in AKT2, KMT2C, and KMT2D as negative predictors of local-regional control and survival, and deleterious mutations in damage response and repair pathway genes were associated with improved local-regional disease control after chemoradiation therapy. These findings will require validation in a larger cohort of patients with prospectively collected and detailed clinical information.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Luo LY, Samstein RM, Dick-Godfrey R, et al. Genomic Analyses for Predictors of Response to Chemoradiation in Stage III Non-Small Cell Lung Cancer. Adv Radiat Oncol. 2020. PMID: 33665490. doi:10.1016/j.adro.2020.10.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。